Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Pediatrics and Neonatology
  • Pediatrics and Neonatology News
  • CBD gel reduces...

CBD gel reduces seizures in children with DEE: BELIEVE trial

Medha BaranwalWritten by Medha Baranwal Published On 2021-01-05T18:15:31+05:30  |  Updated On 2021-08-20T16:16:24+05:30
CBD gel reduces seizures in children with DEE: BELIEVE trial

Australia: Cannabidiol (CBD) transdermal gel (ZYN002, Zygel) helped to reduce seizure frequency in children and adolescents with developmental and epileptic encephalopathies (DEE), show results from phase II BELIEVE trial.The findings of the study were presented at the American Epilepsy Society 2020 virtual annual meeting. DEE are the most severe group of epilepsies....

Australia: Cannabidiol (CBD) transdermal gel (ZYN002, Zygel) helped to reduce seizure frequency in children and adolescents with developmental and epileptic encephalopathies (DEE), show results from phase II BELIEVE trial.

The findings of the study were presented at the American Epilepsy Society 2020 virtual annual meeting. 

DEE are the most severe group of epilepsies. Children have drug-resistant seizures, developmental slowing often with regression, and psychiatric and motor disabilities. BELIEVE trial by Ingrid Scheffer, the University of Melbourne, Australia, and colleagues evaluated the safety, tolerability, and efficacy of cannabidiol transdermal gel in children and adolescents with DEEs. 

BELIEVE was an exploratory open‐label, multiple‐dose study of ZYN002 CBD transdermal gel in children and adolescents (aged 3 to < 18 years) with DEEs. During a 26‐week treatment period, weight-based doses of ZYN002 125, 250, 375, or 500 mg were applied every 12 hours.  After a 4-week baseline period, the children were treated with ZYN002 at a twice daily dose of 125mg (< 25kg) or 250mg ( >25kg). Doses could be titrated up to a dose of 375mg (< 25kg) or 500mg ( >25kg) twice a day.

Primary outcomes were safety and median percent change from baseline in the monthly (28‐day) seizure frequency over 26 weeks. Caregivers used daily diaries to record the number of countable seizures by seizure type. Absence, myoclonic, and focal aware (non‐motor) seizures were also evaluated daily. Safety and tolerability assessments included adverse events, examination of skin, vital signs, and clinical laboratory test. 

In the 26‐week treatment period, of the 48 participants (26 male) enrolled and analyzed for safety, 46 were evaluated for efficacy. 

Key findings of the study include:

  • 60.4% patients had at least 1 treatment-related adverse event over 26 weeks, of which 93% were mild or moderate.
  • The most frequent were application site dryness, application site pain, and somnolence, each 8.3%.
  • The percentage of patients with a new onset drug-related adverse event decreased from 38% at Week 4 to 3% at Week 26.
  • In 33 patients with focal impaired awareness seizures and/or tonic-clonic seizures at baseline, there was up to 58% median monthly reduction in these seizure types from Week 8 to Week 26 and up to 63% of these patients experienced a ≥50% reduction in monthly seizure frequency during this time period.

"ZYN002 CBD transdermal gel was well tolerated and data suggest reduced seizure frequency in children and adolescents with a DEE. This positive benefit‐risk profile supports further study of ZYN002 in this difficult to treat population," concluded the authors. 

ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Developmental and Epileptic Encephalopathies: An Open-Label Clinical Trial was presented at the AES 2020. 

American Epilepsy Society Cannabidiol seizures 
Source : AES 2020
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X